Deregulation of the DNA-methylating machinery is associated with neoplastic transformation of many types of cells in humans. Both general genomic hypomethylation and regional hypermethylation coexist in DNA extracted from different types of neoplastic tissues. A number of studies have sought to reconcile this apparent paradox, suggesting that in solid cancers, the high frequency of DNA hypomethylation, the nature of the affected sequences and the absence of associations with DNA hypermethylation are consistent with an independent role of DNA undermethylation in the development of these solid neoplasms.
Promoter hypermethylation and global hypomethylation are independent epigenetic events in lymphoid leukemogenesis with opposing effects on clinical outcome Deregulation of the DNA-methylating machinery is associated with neoplastic transformation of many types of cells in humans. Both general genomic hypomethylation and regional hypermethylation coexist in DNA extracted from different types of neoplastic tissues. A number of studies have sought to reconcile this apparent paradox, suggesting that in solid cancers, the high frequency of DNA hypomethylation, the nature of the affected sequences and the absence of associations with DNA hypermethylation are consistent with an independent role of DNA undermethylation in the development of these solid neoplasms. 1, 2 We have recently shown that the methylation of cytosine nucleotides in acute lymphoblastic leukemia (ALL) cells is the most important way to inactivate cancer-related genes in this disease. In fact, this epigenetic event can help to inactivate tumor-suppressive apoptotic or growth-arresting responses and has prognostic impact in B-and T-ALL. 3, 4 The presence in individual tumors of multiple genes simultaneously methylated (a condition termed CpG island methylator phenotype or CIMP þ ) is an independent factor of poor prognosis in both childhood and adult ALL in terms of disease-free survival (DFS) and overall survival (OS). However, no studies have addressed the role of hypomethylation in lymphoid leukemogenesis and therefore, it is unclear whether these epigenetic changes are causally linked, or are distinct and biologically unrelated phenomena.
In the present study, we analyzed the extent of both DNA hypomethylation and hypermethylation in 307 consecutive patients (179 men; 128 women) who were diagnosed with de novo ALL between January 1989 and December 2004 (median age at diagnosis in the study population as a whole was 14 years). Methylation-specific PCR (MSP) method was used to analyze 39 genes belonging to all of the molecular pathways involved in cell immortalization and transformation: cell cycle (FHIT, LATS2, p15, p16, p57, REPRIMO and RIZ), cell adherence and metastasis process (ADAMTS1, ADAMTS5, CDH1 and CDH13), p53 network (ASPP1, p14 and p73), apoptosis (APAF1, ARTS, DAPK, DBC1, DIABLO and TMS1,), inhibitors of the oncogenic WNT signaling pathway (DKK3, HDPR1, sFRP1, sFRP2, sFRP4, sFRP5 and WIF1), differentiation regulation (LHX2 and NES1), folate carrier (hRFC), hormone receptor superfamily (PGR), ubiquitination (PACRG and PARK2), DNA repair (SMC1L1 and SMC1L2), tyrosine kinase with an essential role in signal transduction (SYK), negative regulator of the Jak/STAT signaling pathway (SHP1) and main tumor-suppressor genes (LATS1 and PTEN). Hypomethylation of the LINE1 (L1) retrotransposons (as indicator of genomic global hypomethylation) was assessed by means of a quantitative real-time MSP as previously described by our group. 5 Gene methylation frequencies varied from 8 to 59%. Twentythree genes demonstrated a relatively high frequency of aberrant methylation:
, DIABLO (22%) and sFRP4 (21%). The other 16 genes studied showed a low frequency (8-19%) of methylation. No methylated genes were found in 45 of 307 patients (15%), whereas most ALLs (262 (85%) of 307) had methylation of at least one gene, ranging from one to 25 methylated genes. According to the number of methylated genes observed in each individual sample, 106 patients (35%) were included in the CIMPÀ group (0-2 methylated genes) and 201 (65%) in the CIMP þ group (more than two methylated genes). As shown in Table 1 , clinical and laboratory characteristics did not differ significantly between methylation groups. Table 1 also details the relapse history, complete remission (CR) rates and mortality for patients included in the different methylation groups. CR rates of patients in the CIMPÀ and CIMP þ groups were 91 and 87%, respectively, accounting for 89% of the overall CR rate. This suggests that methylation profile did not correlate with response to remission-induction therapy. However, patients in the CIMPÀ group had a lower relapse rate than patients in the CIMP þ group (26 versus 58%, Po0.0001). Mortality rate was also lower for CIMPÀ group compared with CIMP þ group (34 versus 58%, Po0.001). Similar results were obtained in the separate analyses of children (relapse rate, 14% for CIMPÀ group versus 45% for CIMP þ group, Po0.001; mortality rate, 12% for CIMPÀ group versus 31% for CIMP þ group, P ¼ 0.01) and adults (relapse rate, 42% for CIMPÀ group versus 72% for CIMP þ group, P ¼ 0.002; mortality rate, 58% for CIMPÀ group versus 82% for CIMP þ group, P ¼ 0.004).
We analyzed the DFS among patients who achieved CR according to the methylation profile. Estimated DFS at 14 years were 68 and 32% for CIMPÀ and CIMP þ groups, respectively (Po0.0001; Figure 1a ). The actuarial OS at 14 years calculated for all leukemic patients was 63% for CIMPÀ patients and 32% for CIMP þ patients (P ¼ 0.0002; Figure 1b) . A multivariate analysis of potential prognostic factors demonstrated that hypermethylation profile was an independent prognostic factor Kaplan-Meier survivor function for ALL patients according to the methylation profile. DFS (a) and OS (b) curves for all the patients enrolled in this study according to the methylation profile. CIMPÀ (patients with 0-2 methylated genes); CIMP þ (patients with more than two methylated genes).
Letter to the Editor in predicting DFS in the global series (Po0.0001) as well as in both childhood (P ¼ 0.001) and adult ALLs (P ¼ 0.001). Methylation status was also independently associated with OS in the global series (P ¼ 0.003), adult ALL (P ¼ 0.03) and childhood ALL (P ¼ 0.05).
L1 promoter was hypomethylated in 73/307 (24%) of ALL patients. We found no significant associations between the methylation status of any of the 39 studied CpG-rich regions and L1 hypomethylation levels. Moreover, L1 hypomethylation was similarly distributed among CIMPÀ and CIMP þ groups (26 versus 23%, Table 1 ).
Hypomethylated patients had lower relapse (33 versus 55%, P ¼ 0.01) and mortality (35 versus 48%, P ¼ 0.04) rates than normally methylated patients. Estimated DFS rates at 12 years were 63 and 38% for hypomethylated and normal patients, respectively (P ¼ 0.02, Figure 2a) . The actuarial OS calculated for all leukemic patients was 61 and 43% at 12 years for cases with hypomethylated and normal L1, respectively (P ¼ 0.03, Figure 2b) . A multivariate analysis demonstrated that L1 hypomethylation was an independent prognostic factor in predicting DFS (P ¼ 0.05) and OS (P ¼ 0.05) in the global series. Interestingly, L1 hypomethylation was able to redefine the prognosis of the CIMPÀ patients, establishing a very low-risk ALL group. Among CIMPÀ patients, the 12-year DFS was 100% for L1-hypomethylated group and 50% for L1-methylated group (P ¼ 0.004; Figure 2c ). The actuarial OS at 12 years for the same patients was 81% for hypomethylated patients and 58% for methylated patients (P ¼ 0.08; Figure 2d ).
Our analysis of the abnormal DNA methylation patterns reveals the ubiquity of the epigenetic alterations in ALL.
Hypermethylation of multiple genes is a common phenomenon; 85% of cases had at least one gene methylated, whereas 65% of cases had three or more genes methylated. In addition, we also report for the first time that most ALL tumors display global genomic hypomethylation, as has been described for some other types of cancer. Importantly, we found no association between the extent of methylation of any of the 39 CpG-rich regions or the CIMP status in the 307 ALL samples analyzed and their global DNA methylation levels. The absence of any such relationship suggests that tumor-associated DNA hypomethylation contributes to lymphoid leukemogenesis separately from aberrant DNA hypermethylation and its attendant silencing of tumor suppressor genes.
In this paper, analyzing a larger series of patients with a longer follow-up and a more extensive number of genetic loci, we have confirmed our previous observation that aberrant methylation of CpG islands provides important prognostic information in ALL patients. 3, 4 The presence in individual tumors of multiple genes simultaneously methylated is a factor of poor prognosis in ALL. In contrast, DNA hypomethylation was an indicator of good prognosis in both univariate and multivariate analyses and was able to define a very low-risk ALL group among CIMPÀ patients. This opposite association of the hyper-and hypomethylation with patient outcome is also consistent with the independent roles of both abnormalities in tumor initation and progression described above.
Although genome-wide DNA hypomethylation has been observed in a wide variety of human cancers, the functional significance of this alteration is still unclear. In human leukemogenesis, we have recently demonstrated that L1 Letter to the Editor promoter hypomethylation is an important feature in chronic myeloid leukemia (CML). 5 In fact, hypomethylation increased from chronic phase CML toward advanced phase CML, this hypomethylation being the most common molecular abnormality associated with blastic crisis reported to date and suggesting that hypomethylation has a limited role in the genesis of CML but is important in the progression of the disease. These data seem to be in disagreement with our current results in ALL in which DNA hypomethylation can promote early events in leukemogenesis while blocking progression and dismal prognosis. These dual effects of DNA hypomethylation on neoplastic cells have been previously reported. Several experiments have demonstrated that global DNA hypomethylation significantly suppresses intestinal tumorigenesis in mice. 6 In contrast, global DNA hypomethylation promotes chromosomal instability in mice, which results in the development of T-cell lymphomas and also accelerates tumor formation in murine sarcoma model. 7 Moreover, hypomethylation promotes earlystage tumor formation in the colon and liver tumorigenesis but strongly suppresses overall tumorigenesis in the intestine of APC Min/ þ mice. 8 Taken together, all these studies and our present report suggest that the reduction of the DNA methylation levels results in suppression or promotion of tumor progression depending on the tumor cell type, including the hematopoietic cell origin of the leukemia.
In conclusion, promoter hypermethylation and global hypomethylation contribute separately to the process of lymphoid leukemogenesis and have opposing effects on clinical outcome. The technique of polymerase chain reaction (PCR) amplification of polymorphic short tandem repeat (STR) markers coupled with fluorescence detection is used widely for monitoring hematopoietic chimerism in patients undergoing allogeneic stem cell transplantation (SCT). [1] [2] [3] [4] [5] [6] [7] However, it is becoming clear that the accuracy and reliability of quantitative chimerism analysis in post-transplant samples are greatly affected by factors such as the homozygosity/heterozygosity of alleles, sharing of donor and patient alleles and the positional relationship of PCR amplicons during analysis. Despite this, there are no generally accepted criteria for the eligibility of an STR marker for chimerism analysis in a transplant recipient on the basis of the allelic configuration. This was rapidly identified as a major problem after establishment of the Eurochimerism consortium, a European working party for the development of harmonized protocols for chimerism analysis. The members of this group have therefore developed a common descriptive nomenclature for the allelic configuration, termed the RSD (Recipient-SharedDonor) code. Herein, we present the principle of the RSD code and discuss its application in the selection of eligible microsatellite markers for the monitoring of chimerism.
We have recognized a number of problems, inherent in the STR-PCR technology, which may affect the eligibility of markers for chimerism testing and the accuracy of quantitative analysis. These are as follows:
1. Stutter peak formation. This phenomenon is caused by slippage of the polymerase during the amplification process of STR markers 8 and leads to the skipping or addition of one or
